MedPath

Long-term Follow-up of Subfoveal Neovascular AMD

Conditions
Exudative Age-related Macular Degeneration
Registration Number
NCT01608113
Lead Sponsor
Medical University of Vienna
Brief Summary

Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study. Patients will be investigated for the first 2 years monthly and subsequently according to disease activity but at least every two months. Patients will be examined with 4m BCVA ETDRS distance visual acuity, reading acuity measured by Radner-Reading-Charts, contrast sensitivity by Pelli-Robson score, microperimetry and HD-OCT.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
70
Inclusion Criteria
  • treatment naive subfoveal AMD, written informed consent, able to read
Exclusion Criteria
  • choroidal neovascularisation due to other ocular diseases, mature cataract

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Long-term visual function performancefour years
Secondary Outcome Measures
NameTimeMethod
change of morphological alterations assessed by SD-OCTfour years

Trial Locations

Locations (1)

Department of Ophthalmology Medical University of Vienna

🇦🇹

Vienna, Austria

Department of Ophthalmology Medical University of Vienna
🇦🇹Vienna, Austria
Jasmin Mittermüller
Contact
00431404004847
Germana Armberger
Contact
00431404004847
Florian Sulzbacher, MD
Sub Investigator
Marion Munk, MD
Sub Investigator
Philipp Roberts, MD
Sub Investigator
Katharina Eibenberger, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.